Suppr超能文献

医疗保险D部分,两年后。

Medicare part D after 2 years.

作者信息

Joyce Geoffrey F, Goldman Dana P, Vogt William B, Sun Eric, Jena Anupam B

机构信息

RAND Corporation, Santa Monica, CA 90407-2138, USA.

出版信息

Am J Manag Care. 2009 Aug;15(8):536-44.

Abstract

OBJECTIVE

To assess the broad impacts of Medicare Part D and the extent to which prior concerns have been realized.

METHODS

We used administrative data to summarize beneficiary enrollment and plan participation in Part D, and compared pharmaceutical use and out-of-pocket spending before and after the introduction of Part D. We characterized the benefit designs of the 10 largest Part D plans in 2006 and compared them with the benefit designs of 7 non-Part D plans often cited as examples of low-cost or comprehensive drug benefits.

RESULTS

By 2008, nearly 90% of seniors had drug coverage at least as generous as the standard Part D benefit. Excluding premiums, annual out-of-pocket spending in the 10 largest Part D plans was comparable to that of other private and public drug benefits, with the most prominent differences attributable to out-of-pocket spending on drugs not covered in the plan. Poorer beneficiaries have gained the most from Part D in terms of increased access to medications and reduced out-of-pocket spending.

CONCLUSIONS

Coverage under Part D is comparable to that under non-Part D plans with respect to key features that are likely to be important to Medicare beneficiaries--access to medications and out-of-pocket costs. Nonetheless, concerns remain over drug pricing and gaps in coverage. The government should continue to monitor the competitiveness of the Part D market to ensure it meets the diverse needs of Medicare beneficiaries.

摘要

目的

评估医疗保险D部分的广泛影响以及先前担忧得以实现的程度。

方法

我们使用行政数据总结了D部分的受益人参保情况和计划参与情况,并比较了D部分推出前后的药品使用和自付费用。我们对2006年最大的10个D部分计划的福利设计进行了特征描述,并将它们与7个常被引为低成本或全面药品福利示例的非D部分计划的福利设计进行了比较。

结果

到2008年,近90%的老年人拥有至少与标准D部分福利一样慷慨的药品保险。排除保费后,最大的10个D部分计划中的年度自付费用与其他私人和公共药品福利相当,最显著的差异归因于计划未涵盖药品的自付费用。就增加药品获取和减少自付费用而言,较贫困的受益人从D部分中获益最多。

结论

在可能对医疗保险受益人很重要的关键特征——药品获取和自付费用方面,D部分的保险与非D部分计划的保险相当。尽管如此,对药品定价和保险缺口的担忧仍然存在。政府应继续监测D部分市场的竞争力,以确保其满足医疗保险受益人的多样化需求。

相似文献

1
Medicare part D after 2 years.
Am J Manag Care. 2009 Aug;15(8):536-44.
2
Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017.
J Manag Care Spec Pharm. 2020 Apr;26(4):562-567. doi: 10.18553/jmcp.2020.26.4.562.
5
Coverage for hepatitis C drugs in Medicare Part D.
Am J Manag Care. 2016 May;22(6 Spec No.):SP220-6.
6
Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
JAMA Intern Med. 2021 Dec 1;181(12):1605-1611. doi: 10.1001/jamainternmed.2021.5997.
7
Prescription Drug Spending in Fee-for-Service Medicare, 2008-2019.
JAMA. 2022 Oct 18;328(15):1515-1522. doi: 10.1001/jama.2022.17825.
8
The Effect of Medicare Part D on Prescription Drug Spending and Health Care Use: 6 Years of Follow-up, 2007-2012.
J Manag Care Spec Pharm. 2017 Jan;23(1):5-12. doi: 10.18553/jmcp.2017.23.1.5.
9
Prescription coverage, use and spending before and after Part D implementation: a national longitudinal panel study.
J Gen Intern Med. 2010 Jan;25(1):10-7. doi: 10.1007/s11606-009-1134-2. Epub 2009 Oct 31.
10
Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
JAMA Health Forum. 2023 May 5;4(5):e231090. doi: 10.1001/jamahealthforum.2023.1090.

引用本文的文献

1
Pharmaceutical policies: effects of regulating drug insurance schemes.
Cochrane Database Syst Rev. 2022 May 3;5(5):CD011703. doi: 10.1002/14651858.CD011703.pub2.
2
The Effect of Medicare Part D on Prescription Drug Spending and Health Care Use: 6 Years of Follow-up, 2007-2012.
J Manag Care Spec Pharm. 2017 Jan;23(1):5-12. doi: 10.18553/jmcp.2017.23.1.5.
3
Pharmaceutical policies: effects of cap and co-payment on rational use of medicines.
Cochrane Database Syst Rev. 2015 May 8;2015(5):CD007017. doi: 10.1002/14651858.CD007017.pub2.
4
How Did Medicare Part D Affect Racial and Ethnic Disparities in Drug Coverage?
J Gerontol B Psychol Sci Soc Sci. 2016 May;71(3):581-9. doi: 10.1093/geronb/gbu170. Epub 2014 Dec 22.
5
Digesting the doughnut hole.
J Health Econ. 2013 Dec;32(6):1345-55. doi: 10.1016/j.jhealeco.2013.04.007. Epub 2013 May 6.
6
Medicare Part D plan generosity and medication use among dual-eligible nursing home residents.
Med Care. 2013 Oct;51(10):894-900. doi: 10.1097/MLR.0b013e31829fafdc.
7
Medicare part D's impact on antipsychotic drug use and costs among elderly patients without prior drug insurance.
J Clin Psychopharmacol. 2012 Feb;32(1):3-10. doi: 10.1097/JCP.0b013e31823fb5c4.
9
Changes in drug use and out-of-pocket costs associated with Medicare Part D implementation: a systematic review.
J Am Geriatr Soc. 2010 Sep;58(9):1764-79. doi: 10.1111/j.1532-5415.2010.03025.x.

本文引用的文献

3
The effect of the Medicare Part D prescription benefit on drug utilization and expenditures.
Ann Intern Med. 2008 Feb 5;148(3):169-77. doi: 10.7326/0003-4819-148-3-200802050-00200. Epub 2008 Jan 7.
4
The impact of Medicare Part D on prescription drug use by the elderly.
Health Aff (Millwood). 2007 Nov-Dec;26(6):1735-44. doi: 10.1377/hlthaff.26.6.1735.
5
Pharmacy benefit caps and the chronically ill.
Health Aff (Millwood). 2007 Sep-Oct;26(5):1333-44. doi: 10.1377/hlthaff.26.5.1333.
7
Status report on Medicare Part D enrollment in 2006: analysis of plan-specific market share and coverage.
Health Aff (Millwood). 2007 Jan-Feb;26(1):w1-12. doi: 10.1377/hlthaff.26.1.w1. Epub 2006 Nov 21.
8
Unintended consequences of caps on Medicare drug benefits.
N Engl J Med. 2006 Jun 1;354(22):2349-59. doi: 10.1056/NEJMsa054436.
9
Medicare prescription drug coverage: consumer information and preferences.
Proc Natl Acad Sci U S A. 2006 May 16;103(20):7929-34. doi: 10.1073/pnas.0601837103. Epub 2006 May 8.
10
Reporting of drug expenditures in the MCBS.
Health Care Financ Rev. 2003 Winter;25(2):23-36.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验